Resistance

Mutations conferring resistance to delavirdine (Rescriptor) tend to occur at codon 103, and less frequently at codons 181 and 236 of the reverse transcriptase gene. HIV that has developed resistance to delavirdine is likely to be resistant to the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune), but there is some evidence that efavirenz (Sustiva) might still be effective against it, particularly if mutation Y181I/C has developed. Other mutations reported to cause reduced susceptibility to delavirdine include M230L, P236L, L100I, K101E/Q, K103S, V106A/M, Y188L, K238N/T and Y318F.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.